Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deciphering the multi-organ anti-fibrotic mechanisms of pirfenidone and nintedanib via network pharmacology.

Personalized medicine·2026
Same author

Network pharmacology, molecular docking and molecular dynamics analysis reveal multi-target mechanisms of Imperata cylindrica (L.) Raeusch. phytoconstituents against rheumatoid arthritis.

Annales pharmaceutiques francaises·2026
Same author

Xanthine oxidase inhibition by medicinal plants mitigates tenofovir-induced nephrotoxicity: a comprehensive computational and experimental study.

Frontiers in pharmacology·2026
Same author

Editorial: Targeted drug delivery and mode of action of small molecules in neuroinflammation.

Frontiers in pharmacology·2026
Same author

NeuroBACE-ML: A reliability-aware screening framework for high-throughput prioritization of potent BACE1 inhibitors.

Journal of molecular graphics & modelling·2026
Same author

Translational Geroscience Strategies for Delaying Multimorbidity.

ACS pharmacology & translational science·2026

Related Experiment Video

Updated: Jun 17, 2025

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

7.9K

Exploring the globoid cell leukodystrophy protein network and therapeutic interventions.

Pukar Khanal1,2, Vishal S Patil3, Kunal Bhattacharya4,5

  • 1Department of Pharmacology, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research (KAHER), Belagavi, 590010, India. pukarkhanal58@gmail.com.

Scientific Reports
|August 5, 2024
PubMed
Summary

Globoid cell leukodystrophy research identified key proteins and a potential drug, T-5224, targeting the Jun/CRE complex. Computational studies show T-5224 may offer a novel therapeutic strategy for this rare white matter disorder.

Keywords:
Computational pharmacologyGloboid cell leukodystrophyKrabbe diseaseRare diseasec-Jun

More Related Videos

Production and Use of Lentivirus to Selectively Transduce Primary Oligodendrocyte Precursor Cells for In Vitro Myelination Assays
10:00

Production and Use of Lentivirus to Selectively Transduce Primary Oligodendrocyte Precursor Cells for In Vitro Myelination Assays

Published on: January 12, 2015

14.5K
Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
07:14

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae

Published on: February 25, 2022

5.9K

Related Experiment Videos

Last Updated: Jun 17, 2025

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

7.9K
Production and Use of Lentivirus to Selectively Transduce Primary Oligodendrocyte Precursor Cells for In Vitro Myelination Assays
10:00

Production and Use of Lentivirus to Selectively Transduce Primary Oligodendrocyte Precursor Cells for In Vitro Myelination Assays

Published on: January 12, 2015

14.5K
Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
07:14

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae

Published on: February 25, 2022

5.9K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Globoid cell leukodystrophy is a rare, severe white matter disorder causing progressive neurological decline.
  • Current therapeutic interventions for this condition are extremely limited.

Purpose of the Study:

  • To identify druggable targets and potential small molecule therapeutics for Globoid cell leukodystrophy.
  • To analyze the disease-associated neuronal protein interaction network.

Main Methods:

  • Differential gene expression analysis to identify disease-associated genes (p < 0.05, |Fc| > 1).
  • Construction and analysis of a neuronal protein circuit to identify core protein nodes.
  • In silico drug discovery including molecular docking and dynamics simulations to evaluate T-5224 efficacy against the Jun/CRE complex.

Main Results:

  • Five core protein nodes (FOS, FOSB, GDNF, GFRA1, JUN) were identified in the disease network.
  • The small molecule T-5224 demonstrated significant binding affinity to the Jun/CRE complex (binding energy: -11.0 kcal/mol).
  • Molecular dynamics simulations confirmed stable hydrophilic interactions and structural integrity of the T-5224-Jun/CRE complex.

Conclusions:

  • JUN is a pivotal protein in Globoid cell leukodystrophy pathogenesis, making the Jun/CRE complex a promising therapeutic target.
  • T-5224 shows potential as a therapeutic agent for Globoid cell leukodystrophy by inhibiting c-Jun activity.
  • Further in vitro and in vivo studies are proposed to validate T-5224's therapeutic potential.